Prescription Medicines
Cansata Tab. 16mg
- Product Category
- ARB-based high blood pressure treatment
- Active Ingredients
- candesartan cilexetil
- Appearance
- A light pink, round, biconvex tablet with a score line on one side.
- Reimbursement Code
- 648102970
01 / 02
1. Composition and Strength : 1 tablet
- Active ingredient: Candesartan cilexetil (JP) ---------- 16mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: magnesium stearate, corn starch, red iron oxide, calcium carboxymethyl cellulose, polyethylene glycol 400, hydroxypropyl cellulose
2. Efficacy/Effectiveness
1. Essential hypertension
2. Heart failure: Among heart failure patients with impaired left ventricular systolic function (NYHA class Ⅱ ∼ Ⅳ, left ventricular ejection fraction 40% or less), the following cases apply:
1) When additional therapy with ACE inhibitors is necessary
2) Cases with poor tolerance to ACE inhibitors
3. Usage/Dosage
This medicine should be taken at a certain time every day, regardless of meals.
1. Essential hypertension
1) Adults: Oral administration of 8 to 16 mg of candesartan cilexetil once a day is recommended as the initial and maintenance dose. Even after 4 weeks of treatment with 16 mg once a day, blood pressure remains sufficiently high.
If not controlled, the dose may be increased up to 32 mg once daily. If blood pressure is not controlled with this dose, other treatments should be considered. Within 4 weeks of starting treatment
The best effect is achieved.
2) Elderly: There is no need to adjust the initial dose.
3) Patients with intravascular volume depletion: Pay close attention to patients with a high risk of hypotension such as effective blood volume depletion.
The initial dose is 4 mg.
4) Patients with renal impairment: The initial dose for patients with renal impairment, including hemodialysis patients, is 4 mg, and the dose is adjusted according to the patient's response. Patients with severe or end-stage renal impairment (creatinine clearance)
< 15 mL/min), there is limited experience with use.
5) Patients with hepatic impairment: The initial dose for patients with mild and moderate hepatic impairment is 2 mg once a day, and the dose is adjusted according to the patient's response. There is no experience of use in patients with severe hepatic impairment.
6) Children: Safety and effectiveness for adolescents and children under 18 years of age have not been established.
2. Heart failure
1) Adults: The recommended initial dose is 4 mg once a day. Doubling the dose at intervals of at least 2 weeks or more, up to a maximum of 32 mg once a day, considering the patient's tolerance.
The amount can be increased.
2) Elderly patients, patients with reduced effective blood volume within blood vessels, patients with renal impairment, and patients with mild to moderate hepatic impairment: There is no need to adjust the initial dose.
3) Children: Safety and effectiveness for adolescents and children under 18 years of age have not been established.
4. Precautions for use
1. Warning
When drugs that act directly on the renin-angiotensin-aldosterone system (RAAS) are administered to pregnant women, damage and even death may occur in the fetus and newborn. Dozens of such cases have been reported worldwide, even in patients taking ACE inhibitors. Therefore, if pregnancy is confirmed, administration of this drug should be discontinued immediately.
(Refer to the ‘Administration for pregnant and lactating women’ section).
2. Do not administer to the following patients.
1) Patients with hypersensitivity to this drug or its components
2) Pregnant women, women who may be pregnant, and lactating women
3) Patients with severe hepatic impairment and/or cholestasis
4) Patients with hereditary angioedema or a history of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists
5) Patients with primary hyperaldosteronism (do not respond well to this drug)
6) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
3. Administer with caution to the following patients.
1) Elderly people
2) Patients with hyperkalemia or patients prone to elevated serum potassium levels
3) Patients with mild to moderate liver impairment (e.g., patients with cirrhosis)
4) Patients with aortic and mitral valve stenosis or obstructive hypertrophic cardiomyopathy
5) Patients with ischemic heart disease, ischemic cardiovascular disease, and cerebrovascular disorder (excessive drop in blood pressure can cause myocardial infarction or stroke due to cerebral blood flow failure.)
6) Patients with bilateral or unilateral renal artery stenosis (there is a risk of rapid deterioration of renal function due to a decrease in renal blood flow or a decrease in glomerular filtration pressure).
7) Patients with reduced intravascular effective blood volume
8) Patients with renal impairment (there is a risk that renal function may worsen due to excessive pressure.)
9) Patients who recently received a kidney transplant (no experience using it)
10) Children and adolescents under 18 years of age
4. Adverse reactions
1) Essential hypertension
In general, adverse reactions were mild and transient, and the incidence was independent of dose, age, and gender. Cases of discontinuation of treatment due to adverse reactions were similar in the drug and placebo groups.
(1) As a result of the clinical trial, the adverse reactions that occurred at least 1% in the candesartan cilexetil group and at a higher rate than the placebo group are as follows.
① Mental nervous system: dizziness
② Musculoskeletal system: back pain
③ Respiratory system: Respiratory infection (upper respiratory infection, pharyngitis, rhinitis)
(2) As a result of clinical trials, adverse reactions occurred at a rate of 1% or more, but occurred at the same or higher rate in the placebo group compared to this drug, as follows. : Fatigue, peripheral edema, chest pain, headache, bronchitis, cough, sinusitis, nausea, abdominal pain, diarrhea, vomiting, arthralgia, proteinuria
(3) As a result of clinical trials, the important adverse reactions reported with an incidence of 0.5% or more regardless of causal relationship with this drug are as follows.
① Whole body: Asthenia, fever
② Central and peripheral nervous system: paresthesia, dizziness
③ Digestive system: indigestion, gastroenteritis
④ Cardiovascular system: tachycardia, palpitations
⑤ Metabolism and nutrition: Increased creatine kinase (CK), hyperglycemia, hypertriglyceridemia, hyperuricemia
⑥ Musculoskeletal system: muscle pain
⑦ Platelets and bleeding: Epistaxis
⑧ Mental nervous system: anxiety, depression, drowsiness
⑨ Respiratory system: Difficulty breathing
⑩ Skin and appendages: Rash, increased sweating
⑪ Urinary system: hematuria
2) Heart failure
The pattern of adverse reactions in heart failure patients was consistent with the pharmacological action and the patient's health status. In the CHARM clinical trial comparing the 32 mg of this drug (n=3,803) group and the placebo (n=3,796) group, 21.0% of the drug treated group and 16.1% of the placebo group discontinued treatment due to adverse reactions. Adverse reactions that occurred frequently (≥ 1/100, < 1/10) were hypotension, hyperkalemia, impaired renal function, and increases in creatinine, urea, and potassium. It is recommended to monitor serum potassium and creatinine levels during dose escalation and periodically thereafter.
3) In general, this drug did not have a clinically significant effect on routine laboratory parameters. As with other renin-angiotensin-aldosterone system inhibitors, hemoglobin and hematocrit decreased slightly. Increases in creatinine, urea, and potassium and decreases in sodium were observed. As an adverse reaction, an increase in ALT was reported at a slightly higher frequency in the drug-treated group than in the placebo group (1.3% vs 0.5%). Routine monitoring of laboratory parameters is not necessary in patients receiving this drug, but regular monitoring of serum potassium and creatinine levels is recommended in patients with impaired renal function.
4) Adverse reactions that were very rare (< 1/10,000) or appeared with unknown frequency in post-marketing surveillance are as follows.
(1) Blood and lymphatic system: Leukopenia and neutropenia may occur. Additionally, since agranulocytosis may occur, sufficient observation should be conducted and if abnormalities are recognized, administration should be discontinued and appropriate measures taken.
(2) Metabolic and nutritional abnormalities: Hyperkalemia, hyponatremia, and hypoglycemia (which are prone to occur in patients receiving diabetes treatment) may occur, so observe thoroughly. If helplessness, hunger, cold sweat, hand tremors, poor concentration, convulsions, or impaired consciousness appear, stop administration and take appropriate measures.
(3) Nervous system: Dizziness and headache may occur.
(4) Digestive system: Nausea and diarrhea may occur.
(5) Hepatobiliary system: Increased liver enzyme levels and hepatitis may occur. In addition, liver dysfunction such as elevation of AST, ALT, and γ-GTP and jaundice may occur. Therefore, sufficient observation should be conducted and if abnormalities are recognized, administration should be discontinued and appropriate measures should be taken.
(6) Skin and subcutaneous tissue: Rash, hives, and itching may occur. Additionally, angioedema (swelling of the face, lips, tongue, throat, larynx, etc.) may occur, so observe thoroughly, and if abnormalities are recognized, stop administration and take appropriate measures.
(7) Rhabdomyolysis, characterized by muscle pain, weakness, elevated creatine kinase (CK), and elevated myoglobin in the blood and urine, may occur. Therefore, sufficient observation should be conducted, and in such cases, administration should be discontinued and appropriate measures taken.
(8) Musculoskeletal system: Joint pain, muscle pain, and back pain may occur.
(9) Kidney and urinary system: Impairment of renal function and acute renal failure may occur, so observe thoroughly, and if abnormalities are recognized, discontinue administration and take appropriate measures.
(10) Interstitial pneumonia accompanied by fever, resolution, breathing difficulties, and chest X-ray abnormalities may occur. In such cases, discontinue administration and take appropriate measures, such as administration of corticosteroids.
(11) Shock, syncope, and loss of consciousness (in the case of chronic heart failure, syncope and loss of consciousness are 0.1-5%): Shock and syncope or loss of consciousness due to a drop in blood pressure may occur, so observe sufficiently and take appropriate measures immediately if a cold feeling, vomiting, loss of consciousness, etc. appears. In particular, in patients undergoing hemodialysis, strict salt restriction, taking diuretics, or with heart failure, administration should be started from a small amount and increased gradually while carefully observing the patient's condition.
5) As a result of a post-marketing survey conducted on 15,585 people over 6 years for re-examination in Korea, the case rate of adverse reactions was reported to be 1.06% (166 people/15,585 people) regardless of causal relationship, and of these, 0.82% (128 people/15,585 people) were found to have a causal relationship with this drug. Regardless of causal relationship, dizziness was the most common at 0.30% (47 people), followed by headache at 0.22% (35 people), and cough at 0.17% (26 people). Among these, new adverse reactions that did not appear in pre-market clinical trials are as follows.
(1) Central and peripheral nervous system: paralysis (2 people), hypertonia (1 person)
(2) Whole body: fainting (1 person), facial flushing (1 person), weight gain (1 person), facial edema (1 person)
(3) Gastrointestinal system: dry mouth (2 people)
(4) Mental nervous system: sleep disorder (2 people), decreased libido (1 person), forgetfulness (1 person), anorexia (2 people), increased appetite (1 person)
(5) Sense organs: tinnitus (1 person), sense of taste (1 person)
(6) Reproductive system: Erectile dysfunction (1 person)
5. General precautions
1) For patients with bilateral or unilateral renal artery stenosis, caution should be exercised because, like other agents that act on the renin-angiotensin-aldosterone system (e.g., ACE inhibitors), blood urea and serum creatinine concentrations may increase. A similar effect may occur with angiotensin II receptor antagonists.
2) As with other agents that act on the renin-angiotensin-aldosterone system, symptomatic hypotension may occur due to this drug in patients with heart failure and patients with reduced effective intravascular blood volume (e.g., when receiving high doses of diuretics). Therefore, resolve these symptoms before starting treatment with this drug or reduce the initial dose to 4 mg.
3) Hyperkalemia may occur in patients with heart failure, kidney failure, or diabetes receiving this drug. Regular monitoring of serum potassium is recommended during treatment, especially when used concurrently with potassium-sparing diuretics such as ACE inhibitors and spironolactone. Also, be careful as it may worsen symptoms in patients with hyperkalemia.
4) Changes in renal function may occur in patients who are sensitive to this drug. When administering this drug to patients with renal impairment, serum potassium and creatinine levels should be monitored regularly. Clinical experience in patients with severe or end-stage renal impairment (creatinine clearance <15 mL/min) is limited.
5) Among heart failure patients, periodic renal function evaluation should be performed for those aged 75 years or older or those with impaired renal function, and it is recommended to monitor serum potassium and creatinine levels when increasing the dose. Clinical trials targeting patients with heart failure did not include patients with serum creatinine exceeding 265 mol/L (3 mg/dL).
6) There is no experience of administration to patients who recently received a kidney transplant.
7) In patients whose vascular tone and renal function depend primarily on the activity of the renin-angiotensin-aldosterone system (e.g., patients suffering from renal disease, including congestive heart failure or renal artery infarction), treatment with other drugs affecting this system has been associated with acute hypotension, azotemia, oliguria, or, rarely, acute renal failure. The possibility that similar effects may occur with angiotensin II receptor antagonists cannot be ruled out. As with other blood pressure lowering drugs, excessive blood pressure reduction in patients with ischemic heart disease or ischemic cerebrovascular disease can cause myocardial infarction or stroke.
8) When this drug is used in combination with ACE inhibitors in patients with heart failure, the risk of adverse reactions, especially renal function impairment and hyperkalemia, may increase.
9) In patients receiving angiotensin II receptor antagonists, hypotension may occur during anesthesia and surgery due to inhibition of the renin-angiotensin-aldosterone system. In very rare cases, severe hypotension may occur, requiring intravenous administration of fluids or vasoconstrictors. It is advisable not to administer it 24 hours before surgery.
10) During hemodialysis, blood pressure may become sensitive to AT1-receptor antagonists due to decreased plasma volume and activation of the renin-angiotensin-aldosterone system. Therefore, when administering this drug to hemodialysis patients, blood pressure must be carefully monitored and the dose titrated.
11) Combination with diuretics such as hydrochlorothiazide increases blood pressure lowering effect, and in heart failure, it can be used in combination with other heart failure treatment drugs such as beta blockers, non-potassium sparing diuretics, digitalis, or a mixture of these agents.
12) In patients with high blood pressure, administration of this drug may rarely cause a sudden drop in blood pressure, shock, syncope, transient loss of consciousness, or decreased renal function. Therefore, especially when administering to the following patients, start with a small amount and increase it gradually while carefully observing blood pressure, kidney function, and the patient's condition.
(1) Patients undergoing hemodialysis
(2) Patients undergoing strict salt restriction
(3) Patients taking diuretics
(4) Patients with hyponatremia
(5) Patients with renal impairment
(6) Heart failure patients
13) In patients with heart failure, administration of this drug may cause a rapid drop in blood pressure, decreased kidney function, or anemia. Therefore, especially when administered to the following patients, begin administration and carefully increase the dose while carefully observing blood pressure, kidney function, anemia indicators (hemoglobin, etc.) and the patient's condition.
(1) Patients undergoing hemodialysis
(2) Patients undergoing strict salt restriction
(3) Patients taking diuretics (especially patients who recently started taking diuretics)
(4) Patients with hyponatremia
(5) Patients with renal impairment
(6) Patients with low blood pressure
(7) Patients with relatively severe chronic heart failure such as NYHA class III
14) Among patients with high blood pressure, symptomatic muscle hypotonia may occur in patients with reduced effective intravascular blood volume (e.g., patients receiving high doses of diuretics, etc.).
15) When driving or operating machinery or during treatment for high blood pressure, you should consider that temporary dizziness or fatigue may occur due to a drop in blood pressure. Therefore, be careful when driving a car or operating machinery.
6. Interaction
1) No clinically significant drug interactions have been reported. Substances investigated in clinical pharmacokinetic studies include hydrochlorothiazide, warfarin, digoxin, oral contraceptives (i.e. ethinyl estradiol/levonorgestrel), glibenclamide, and nifedipine.
2) Only a small amount of this drug is eliminated through hepatic metabolism (CYP2C9). Interaction studies showed no effects on CYP2C9 and CYP3A4, and no effects on other CYP-450 isoenzymes are known.
3) The blood pressure lowering effect of this drug may be increased by other blood pressure lowering drugs.
4) When ACE inhibitors and lithium were used together, serum lithium concentration and toxicity were reversibly increased. Because similar effects may occur with angiotensin II receptor antagonists, careful monitoring of serum lithium levels is recommended.
5) When angiotensin II receptor antagonists are used in combination with non-steroidal anti-inflammatory drugs (e.g., selective COX-2 inhibitors, acetylsalicylic acid (> 3 g/day), non-selective non-steroidal anti-inflammatory drugs), the blood pressure lowering effect may be reduced. Like ACE inhibitors, combined use of angiotensin II receptor antagonists and NSAIDs can worsen renal function, cause acute renal failure, and increase serum potassium. Caution must be exercised when using together, especially in the elderly or patients with reduced effective blood volume (including patients receiving diuretic treatment). After starting combination treatment, patients should be provided with adequate fluids and renal function should be monitored periodically.
6) Based on experience with the use of other agents that affect the renin-angiotensin-aldosterone system, caution is advised as serum potassium concentration may increase when this drug is coadministered with potassium-sparing diuretics (spironolactone, triamterene, etc.), potassium supplements, salt supplements containing potassium, or other agents that can increase potassium levels (e.g., heparin).
7) The bioavailability of this drug is not affected by food.
8) The effectiveness and safety of this drug in patients for whom the effect of ACE inhibitors is insufficient, and the effectiveness and safety of this drug when administered in combination with ACE inhibitors, have not been established. When used in combination with ACE inhibitors in patients with heart failure, the risk of adverse reactions such as renal dysfunction and hyperkalemia increases. Therefore, caution must be taken when using together.
9) Since the interaction of this drug with acenocoumarol or phenprocoumone has not been studied, caution should be taken when using this drug together with the above anticoagulants.
10) The combined use of ACE inhibitors, potassium-sparing diuretics, and this drug is not recommended.
7. Administration to pregnant and lactating women
1) Because of the mechanism of action of angiotensin II receptor antagonists, the risk to the fetus cannot be ignored. In pregnant women exposed to ACE inhibitors (a specific class of drugs that act on the renin-angiotensin-aldosterone system) during the second or third trimester of pregnancy, they have been associated with fetal and neonatal harm, including fetal and neonatal hypotension, hyperkalemia, neonatal cranial hypoplasia, urinary retention and/or anuria, reversible or irreversible renal failure, intrauterine growth retardation, and death. Oligohydramnios, presumed to be due to decreased fetal renal function, has been reported, and oligohydramnios has been associated with fetal limb contractures, craniofacial malformations, and pulmonary hypoplasia. Retrospective data suggest that use of ACE inhibitors in the first trimester of pregnancy is associated with a potential risk of birth defects. Additionally, although it is not clear whether this drug is caused by it, there are reports of prematurity, intrauterine growth retardation, and patent ductus arteriosus. Like other drugs that act directly on the renin-angiotensin-aldosterone system, this drug should not be used by women who are pregnant or planning to become pregnant, and if pregnancy is confirmed while taking the drug, the drug should be discontinued immediately. When prescribing drugs that act on the renin-angiotensin-aldosterone system to women who may become pregnant, doctors should inform them of the potential risks of these drugs during pregnancy. If a pregnant woman has been exposed to angiotensin II receptor antagonists beyond the second trimester, fetal renal function and cranial ultrasound examination is recommended. Additionally, neonates who have been exposed to this drug in utero should be closely monitored for sufficient urination, hyperkalemia, and blood pressure.
2) It is not known whether this drug passes into breast milk, but secretion of this drug in breast milk was confirmed in experiments on rats, so it is not recommended for nursing mothers to use this drug. Avoid administering this drug to breastfeeding women, and if administration is unavoidable, breast-feeding should be discontinued.
8. Administration to children
Safety and effectiveness for adolescents and children under 18 years of age have not been established.
9. Administration to elderly people
In general, excessive lowering of blood pressure is not desirable for elderly people (there is a risk of cerebral infarction, etc.). Therefore, be cautious when administering to elderly people.
10. Treatment in case of overdose
When considered pharmacologically, the main symptoms of overdose are symptomatic hypotension, dizziness, and tachycardia. Recovery occurred in a case of overdose of up to 672 mg of candesartan cilexetil. If hypotension occurs due to overdose, monitor vital signs and treat with the following symptomatic treatment. The patient should lie on his back with his legs up and correct blood volume. If this is not sufficient, sympathomimetics are administered. This drug is not removed by hemodialysis.
11. Storage and handling precautions
1) Be careful to keep it out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle
7. Expiration date
36 months from date of manufacture
- Active ingredient: Candesartan cilexetil (JP) ---------- 16mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: magnesium stearate, corn starch, red iron oxide, calcium carboxymethyl cellulose, polyethylene glycol 400, hydroxypropyl cellulose
2. Efficacy/Effectiveness
1. Essential hypertension
2. Heart failure: Among heart failure patients with impaired left ventricular systolic function (NYHA class Ⅱ ∼ Ⅳ, left ventricular ejection fraction 40% or less), the following cases apply:
1) When additional therapy with ACE inhibitors is necessary
2) Cases with poor tolerance to ACE inhibitors
3. Usage/Dosage
This medicine should be taken at a certain time every day, regardless of meals.
1. Essential hypertension
1) Adults: Oral administration of 8 to 16 mg of candesartan cilexetil once a day is recommended as the initial and maintenance dose. Even after 4 weeks of treatment with 16 mg once a day, blood pressure remains sufficiently high.
If not controlled, the dose may be increased up to 32 mg once daily. If blood pressure is not controlled with this dose, other treatments should be considered. Within 4 weeks of starting treatment
The best effect is achieved.
2) Elderly: There is no need to adjust the initial dose.
3) Patients with intravascular volume depletion: Pay close attention to patients with a high risk of hypotension such as effective blood volume depletion.
The initial dose is 4 mg.
4) Patients with renal impairment: The initial dose for patients with renal impairment, including hemodialysis patients, is 4 mg, and the dose is adjusted according to the patient's response. Patients with severe or end-stage renal impairment (creatinine clearance)
< 15 mL/min), there is limited experience with use.
5) Patients with hepatic impairment: The initial dose for patients with mild and moderate hepatic impairment is 2 mg once a day, and the dose is adjusted according to the patient's response. There is no experience of use in patients with severe hepatic impairment.
6) Children: Safety and effectiveness for adolescents and children under 18 years of age have not been established.
2. Heart failure
1) Adults: The recommended initial dose is 4 mg once a day. Doubling the dose at intervals of at least 2 weeks or more, up to a maximum of 32 mg once a day, considering the patient's tolerance.
The amount can be increased.
2) Elderly patients, patients with reduced effective blood volume within blood vessels, patients with renal impairment, and patients with mild to moderate hepatic impairment: There is no need to adjust the initial dose.
3) Children: Safety and effectiveness for adolescents and children under 18 years of age have not been established.
4. Precautions for use
1. Warning
When drugs that act directly on the renin-angiotensin-aldosterone system (RAAS) are administered to pregnant women, damage and even death may occur in the fetus and newborn. Dozens of such cases have been reported worldwide, even in patients taking ACE inhibitors. Therefore, if pregnancy is confirmed, administration of this drug should be discontinued immediately.
(Refer to the ‘Administration for pregnant and lactating women’ section).
2. Do not administer to the following patients.
1) Patients with hypersensitivity to this drug or its components
2) Pregnant women, women who may be pregnant, and lactating women
3) Patients with severe hepatic impairment and/or cholestasis
4) Patients with hereditary angioedema or a history of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists
5) Patients with primary hyperaldosteronism (do not respond well to this drug)
6) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
3. Administer with caution to the following patients.
1) Elderly people
2) Patients with hyperkalemia or patients prone to elevated serum potassium levels
3) Patients with mild to moderate liver impairment (e.g., patients with cirrhosis)
4) Patients with aortic and mitral valve stenosis or obstructive hypertrophic cardiomyopathy
5) Patients with ischemic heart disease, ischemic cardiovascular disease, and cerebrovascular disorder (excessive drop in blood pressure can cause myocardial infarction or stroke due to cerebral blood flow failure.)
6) Patients with bilateral or unilateral renal artery stenosis (there is a risk of rapid deterioration of renal function due to a decrease in renal blood flow or a decrease in glomerular filtration pressure).
7) Patients with reduced intravascular effective blood volume
8) Patients with renal impairment (there is a risk that renal function may worsen due to excessive pressure.)
9) Patients who recently received a kidney transplant (no experience using it)
10) Children and adolescents under 18 years of age
4. Adverse reactions
1) Essential hypertension
In general, adverse reactions were mild and transient, and the incidence was independent of dose, age, and gender. Cases of discontinuation of treatment due to adverse reactions were similar in the drug and placebo groups.
(1) As a result of the clinical trial, the adverse reactions that occurred at least 1% in the candesartan cilexetil group and at a higher rate than the placebo group are as follows.
① Mental nervous system: dizziness
② Musculoskeletal system: back pain
③ Respiratory system: Respiratory infection (upper respiratory infection, pharyngitis, rhinitis)
(2) As a result of clinical trials, adverse reactions occurred at a rate of 1% or more, but occurred at the same or higher rate in the placebo group compared to this drug, as follows. : Fatigue, peripheral edema, chest pain, headache, bronchitis, cough, sinusitis, nausea, abdominal pain, diarrhea, vomiting, arthralgia, proteinuria
(3) As a result of clinical trials, the important adverse reactions reported with an incidence of 0.5% or more regardless of causal relationship with this drug are as follows.
① Whole body: Asthenia, fever
② Central and peripheral nervous system: paresthesia, dizziness
③ Digestive system: indigestion, gastroenteritis
④ Cardiovascular system: tachycardia, palpitations
⑤ Metabolism and nutrition: Increased creatine kinase (CK), hyperglycemia, hypertriglyceridemia, hyperuricemia
⑥ Musculoskeletal system: muscle pain
⑦ Platelets and bleeding: Epistaxis
⑧ Mental nervous system: anxiety, depression, drowsiness
⑨ Respiratory system: Difficulty breathing
⑩ Skin and appendages: Rash, increased sweating
⑪ Urinary system: hematuria
2) Heart failure
The pattern of adverse reactions in heart failure patients was consistent with the pharmacological action and the patient's health status. In the CHARM clinical trial comparing the 32 mg of this drug (n=3,803) group and the placebo (n=3,796) group, 21.0% of the drug treated group and 16.1% of the placebo group discontinued treatment due to adverse reactions. Adverse reactions that occurred frequently (≥ 1/100, < 1/10) were hypotension, hyperkalemia, impaired renal function, and increases in creatinine, urea, and potassium. It is recommended to monitor serum potassium and creatinine levels during dose escalation and periodically thereafter.
3) In general, this drug did not have a clinically significant effect on routine laboratory parameters. As with other renin-angiotensin-aldosterone system inhibitors, hemoglobin and hematocrit decreased slightly. Increases in creatinine, urea, and potassium and decreases in sodium were observed. As an adverse reaction, an increase in ALT was reported at a slightly higher frequency in the drug-treated group than in the placebo group (1.3% vs 0.5%). Routine monitoring of laboratory parameters is not necessary in patients receiving this drug, but regular monitoring of serum potassium and creatinine levels is recommended in patients with impaired renal function.
4) Adverse reactions that were very rare (< 1/10,000) or appeared with unknown frequency in post-marketing surveillance are as follows.
(1) Blood and lymphatic system: Leukopenia and neutropenia may occur. Additionally, since agranulocytosis may occur, sufficient observation should be conducted and if abnormalities are recognized, administration should be discontinued and appropriate measures taken.
(2) Metabolic and nutritional abnormalities: Hyperkalemia, hyponatremia, and hypoglycemia (which are prone to occur in patients receiving diabetes treatment) may occur, so observe thoroughly. If helplessness, hunger, cold sweat, hand tremors, poor concentration, convulsions, or impaired consciousness appear, stop administration and take appropriate measures.
(3) Nervous system: Dizziness and headache may occur.
(4) Digestive system: Nausea and diarrhea may occur.
(5) Hepatobiliary system: Increased liver enzyme levels and hepatitis may occur. In addition, liver dysfunction such as elevation of AST, ALT, and γ-GTP and jaundice may occur. Therefore, sufficient observation should be conducted and if abnormalities are recognized, administration should be discontinued and appropriate measures should be taken.
(6) Skin and subcutaneous tissue: Rash, hives, and itching may occur. Additionally, angioedema (swelling of the face, lips, tongue, throat, larynx, etc.) may occur, so observe thoroughly, and if abnormalities are recognized, stop administration and take appropriate measures.
(7) Rhabdomyolysis, characterized by muscle pain, weakness, elevated creatine kinase (CK), and elevated myoglobin in the blood and urine, may occur. Therefore, sufficient observation should be conducted, and in such cases, administration should be discontinued and appropriate measures taken.
(8) Musculoskeletal system: Joint pain, muscle pain, and back pain may occur.
(9) Kidney and urinary system: Impairment of renal function and acute renal failure may occur, so observe thoroughly, and if abnormalities are recognized, discontinue administration and take appropriate measures.
(10) Interstitial pneumonia accompanied by fever, resolution, breathing difficulties, and chest X-ray abnormalities may occur. In such cases, discontinue administration and take appropriate measures, such as administration of corticosteroids.
(11) Shock, syncope, and loss of consciousness (in the case of chronic heart failure, syncope and loss of consciousness are 0.1-5%): Shock and syncope or loss of consciousness due to a drop in blood pressure may occur, so observe sufficiently and take appropriate measures immediately if a cold feeling, vomiting, loss of consciousness, etc. appears. In particular, in patients undergoing hemodialysis, strict salt restriction, taking diuretics, or with heart failure, administration should be started from a small amount and increased gradually while carefully observing the patient's condition.
5) As a result of a post-marketing survey conducted on 15,585 people over 6 years for re-examination in Korea, the case rate of adverse reactions was reported to be 1.06% (166 people/15,585 people) regardless of causal relationship, and of these, 0.82% (128 people/15,585 people) were found to have a causal relationship with this drug. Regardless of causal relationship, dizziness was the most common at 0.30% (47 people), followed by headache at 0.22% (35 people), and cough at 0.17% (26 people). Among these, new adverse reactions that did not appear in pre-market clinical trials are as follows.
(1) Central and peripheral nervous system: paralysis (2 people), hypertonia (1 person)
(2) Whole body: fainting (1 person), facial flushing (1 person), weight gain (1 person), facial edema (1 person)
(3) Gastrointestinal system: dry mouth (2 people)
(4) Mental nervous system: sleep disorder (2 people), decreased libido (1 person), forgetfulness (1 person), anorexia (2 people), increased appetite (1 person)
(5) Sense organs: tinnitus (1 person), sense of taste (1 person)
(6) Reproductive system: Erectile dysfunction (1 person)
5. General precautions
1) For patients with bilateral or unilateral renal artery stenosis, caution should be exercised because, like other agents that act on the renin-angiotensin-aldosterone system (e.g., ACE inhibitors), blood urea and serum creatinine concentrations may increase. A similar effect may occur with angiotensin II receptor antagonists.
2) As with other agents that act on the renin-angiotensin-aldosterone system, symptomatic hypotension may occur due to this drug in patients with heart failure and patients with reduced effective intravascular blood volume (e.g., when receiving high doses of diuretics). Therefore, resolve these symptoms before starting treatment with this drug or reduce the initial dose to 4 mg.
3) Hyperkalemia may occur in patients with heart failure, kidney failure, or diabetes receiving this drug. Regular monitoring of serum potassium is recommended during treatment, especially when used concurrently with potassium-sparing diuretics such as ACE inhibitors and spironolactone. Also, be careful as it may worsen symptoms in patients with hyperkalemia.
4) Changes in renal function may occur in patients who are sensitive to this drug. When administering this drug to patients with renal impairment, serum potassium and creatinine levels should be monitored regularly. Clinical experience in patients with severe or end-stage renal impairment (creatinine clearance <15 mL/min) is limited.
5) Among heart failure patients, periodic renal function evaluation should be performed for those aged 75 years or older or those with impaired renal function, and it is recommended to monitor serum potassium and creatinine levels when increasing the dose. Clinical trials targeting patients with heart failure did not include patients with serum creatinine exceeding 265 mol/L (3 mg/dL).
6) There is no experience of administration to patients who recently received a kidney transplant.
7) In patients whose vascular tone and renal function depend primarily on the activity of the renin-angiotensin-aldosterone system (e.g., patients suffering from renal disease, including congestive heart failure or renal artery infarction), treatment with other drugs affecting this system has been associated with acute hypotension, azotemia, oliguria, or, rarely, acute renal failure. The possibility that similar effects may occur with angiotensin II receptor antagonists cannot be ruled out. As with other blood pressure lowering drugs, excessive blood pressure reduction in patients with ischemic heart disease or ischemic cerebrovascular disease can cause myocardial infarction or stroke.
8) When this drug is used in combination with ACE inhibitors in patients with heart failure, the risk of adverse reactions, especially renal function impairment and hyperkalemia, may increase.
9) In patients receiving angiotensin II receptor antagonists, hypotension may occur during anesthesia and surgery due to inhibition of the renin-angiotensin-aldosterone system. In very rare cases, severe hypotension may occur, requiring intravenous administration of fluids or vasoconstrictors. It is advisable not to administer it 24 hours before surgery.
10) During hemodialysis, blood pressure may become sensitive to AT1-receptor antagonists due to decreased plasma volume and activation of the renin-angiotensin-aldosterone system. Therefore, when administering this drug to hemodialysis patients, blood pressure must be carefully monitored and the dose titrated.
11) Combination with diuretics such as hydrochlorothiazide increases blood pressure lowering effect, and in heart failure, it can be used in combination with other heart failure treatment drugs such as beta blockers, non-potassium sparing diuretics, digitalis, or a mixture of these agents.
12) In patients with high blood pressure, administration of this drug may rarely cause a sudden drop in blood pressure, shock, syncope, transient loss of consciousness, or decreased renal function. Therefore, especially when administering to the following patients, start with a small amount and increase it gradually while carefully observing blood pressure, kidney function, and the patient's condition.
(1) Patients undergoing hemodialysis
(2) Patients undergoing strict salt restriction
(3) Patients taking diuretics
(4) Patients with hyponatremia
(5) Patients with renal impairment
(6) Heart failure patients
13) In patients with heart failure, administration of this drug may cause a rapid drop in blood pressure, decreased kidney function, or anemia. Therefore, especially when administered to the following patients, begin administration and carefully increase the dose while carefully observing blood pressure, kidney function, anemia indicators (hemoglobin, etc.) and the patient's condition.
(1) Patients undergoing hemodialysis
(2) Patients undergoing strict salt restriction
(3) Patients taking diuretics (especially patients who recently started taking diuretics)
(4) Patients with hyponatremia
(5) Patients with renal impairment
(6) Patients with low blood pressure
(7) Patients with relatively severe chronic heart failure such as NYHA class III
14) Among patients with high blood pressure, symptomatic muscle hypotonia may occur in patients with reduced effective intravascular blood volume (e.g., patients receiving high doses of diuretics, etc.).
15) When driving or operating machinery or during treatment for high blood pressure, you should consider that temporary dizziness or fatigue may occur due to a drop in blood pressure. Therefore, be careful when driving a car or operating machinery.
6. Interaction
1) No clinically significant drug interactions have been reported. Substances investigated in clinical pharmacokinetic studies include hydrochlorothiazide, warfarin, digoxin, oral contraceptives (i.e. ethinyl estradiol/levonorgestrel), glibenclamide, and nifedipine.
2) Only a small amount of this drug is eliminated through hepatic metabolism (CYP2C9). Interaction studies showed no effects on CYP2C9 and CYP3A4, and no effects on other CYP-450 isoenzymes are known.
3) The blood pressure lowering effect of this drug may be increased by other blood pressure lowering drugs.
4) When ACE inhibitors and lithium were used together, serum lithium concentration and toxicity were reversibly increased. Because similar effects may occur with angiotensin II receptor antagonists, careful monitoring of serum lithium levels is recommended.
5) When angiotensin II receptor antagonists are used in combination with non-steroidal anti-inflammatory drugs (e.g., selective COX-2 inhibitors, acetylsalicylic acid (> 3 g/day), non-selective non-steroidal anti-inflammatory drugs), the blood pressure lowering effect may be reduced. Like ACE inhibitors, combined use of angiotensin II receptor antagonists and NSAIDs can worsen renal function, cause acute renal failure, and increase serum potassium. Caution must be exercised when using together, especially in the elderly or patients with reduced effective blood volume (including patients receiving diuretic treatment). After starting combination treatment, patients should be provided with adequate fluids and renal function should be monitored periodically.
6) Based on experience with the use of other agents that affect the renin-angiotensin-aldosterone system, caution is advised as serum potassium concentration may increase when this drug is coadministered with potassium-sparing diuretics (spironolactone, triamterene, etc.), potassium supplements, salt supplements containing potassium, or other agents that can increase potassium levels (e.g., heparin).
7) The bioavailability of this drug is not affected by food.
8) The effectiveness and safety of this drug in patients for whom the effect of ACE inhibitors is insufficient, and the effectiveness and safety of this drug when administered in combination with ACE inhibitors, have not been established. When used in combination with ACE inhibitors in patients with heart failure, the risk of adverse reactions such as renal dysfunction and hyperkalemia increases. Therefore, caution must be taken when using together.
9) Since the interaction of this drug with acenocoumarol or phenprocoumone has not been studied, caution should be taken when using this drug together with the above anticoagulants.
10) The combined use of ACE inhibitors, potassium-sparing diuretics, and this drug is not recommended.
7. Administration to pregnant and lactating women
1) Because of the mechanism of action of angiotensin II receptor antagonists, the risk to the fetus cannot be ignored. In pregnant women exposed to ACE inhibitors (a specific class of drugs that act on the renin-angiotensin-aldosterone system) during the second or third trimester of pregnancy, they have been associated with fetal and neonatal harm, including fetal and neonatal hypotension, hyperkalemia, neonatal cranial hypoplasia, urinary retention and/or anuria, reversible or irreversible renal failure, intrauterine growth retardation, and death. Oligohydramnios, presumed to be due to decreased fetal renal function, has been reported, and oligohydramnios has been associated with fetal limb contractures, craniofacial malformations, and pulmonary hypoplasia. Retrospective data suggest that use of ACE inhibitors in the first trimester of pregnancy is associated with a potential risk of birth defects. Additionally, although it is not clear whether this drug is caused by it, there are reports of prematurity, intrauterine growth retardation, and patent ductus arteriosus. Like other drugs that act directly on the renin-angiotensin-aldosterone system, this drug should not be used by women who are pregnant or planning to become pregnant, and if pregnancy is confirmed while taking the drug, the drug should be discontinued immediately. When prescribing drugs that act on the renin-angiotensin-aldosterone system to women who may become pregnant, doctors should inform them of the potential risks of these drugs during pregnancy. If a pregnant woman has been exposed to angiotensin II receptor antagonists beyond the second trimester, fetal renal function and cranial ultrasound examination is recommended. Additionally, neonates who have been exposed to this drug in utero should be closely monitored for sufficient urination, hyperkalemia, and blood pressure.
2) It is not known whether this drug passes into breast milk, but secretion of this drug in breast milk was confirmed in experiments on rats, so it is not recommended for nursing mothers to use this drug. Avoid administering this drug to breastfeeding women, and if administration is unavoidable, breast-feeding should be discontinued.
8. Administration to children
Safety and effectiveness for adolescents and children under 18 years of age have not been established.
9. Administration to elderly people
In general, excessive lowering of blood pressure is not desirable for elderly people (there is a risk of cerebral infarction, etc.). Therefore, be cautious when administering to elderly people.
10. Treatment in case of overdose
When considered pharmacologically, the main symptoms of overdose are symptomatic hypotension, dizziness, and tachycardia. Recovery occurred in a case of overdose of up to 672 mg of candesartan cilexetil. If hypotension occurs due to overdose, monitor vital signs and treat with the following symptomatic treatment. The patient should lie on his back with his legs up and correct blood volume. If this is not sufficient, sympathomimetics are administered. This drug is not removed by hemodialysis.
11. Storage and handling precautions
1) Be careful to keep it out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle
7. Expiration date
36 months from date of manufacture
Product Updates
Total 3items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 3 | Cansata Tab. 16mg | Precautions for use | 2026.02.12 | PDF0028_201007652_Precautions for use_Cansata tablet 16mg.pdf |
| 2 | Cansata Tab. 16mg | Precautions for use | 2018.07.31 | PDF0015_201007652_Precautions for use (Cansata tablets 16mg).pdf |
| 1 | Cansata Tab. 16mg | Cansata tablets 16mg (effectiveness, dosage, usage instructions... | 2012.12.31 | HWPCansata Tablet 16mg_Permission change order.hwp |